Skip to main content
SpringerLink
Log in

Practical Approach to the PCOS Patient

  • Reproductive Endocrinology and Infertility (REI) (R Anchan, Section Editor)
  • Published:
Current Obstetrics and Gynecology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The purpose of this review is to provide an overview of polycystic ovary syndrome (PCOS) with a discussion on our current understanding of the pathophysiology and sequela of this syndrome. A diagnostic algorithm, as well as the challenges clinicians may face when evaluating these patients is also included. Clinical treatment strategies for fertility and non-fertility PCOS patients are described in detail.

Recent Findings

Recent discussions on the inaccuracies and lack of standardization for the measurement of androgens, both clinically and chemically, are highlighted. A meta-analysis and a randomized controlled trial evaluating the efficacy of commonly used ovulation induction medications are also included along with recommendations from national committee reports and consensus opinions.

Summary

PCOS is recognized as one of the most common endocrinopathies in women worldwide which continues to attract increased attention and research. Inheritance patterns are multifactorial and may be influenced trans-generationally due to the epigenetic influence of metabolic syndrome. Women with PCOS are at an increased risk of long-term health consequences for which they should be appropriately monitored and treated, in order to decrease the overall morbidity associated with this syndrome. Treatment should be individualized based on the phenotypic presentation of the patient as well as their fertility desires. For some patients, referral to a specialist and multidisciplinary care may be required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of Particular Interest, Published Recently, Have Been Highlighted as: • Of importance •• Of major importance

  1. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544–51.

    Article  PubMed  Google Scholar 

  2. Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod. 2014;29(4):791–801.

    Article  CAS  PubMed  Google Scholar 

  3. Rashidi H, Ramezani Tehrani F, Bahri Khomami M, Tohidi M, Azizi F. To what extent does the use of the Rotterdam criteria affect the prevalence of polycystic ovary syndrome? A community-based study from the Southwest of Iran. Eur J Obstet Gynecol Reprod Biol. 2014;174:100–5.

    Article  PubMed  Google Scholar 

  4. Legro RS, Driscoll D, Strauss 3rd JF, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A. 1998;95(25):14956–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kahsar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril. 2001;75(1):53–8.

    Article  CAS  PubMed  Google Scholar 

  6. Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab. 2006;91(6):2100–4.

    Article  CAS  PubMed  Google Scholar 

  7. Jesintha Mary M, Vetrivel U, Munuswamy D, Melanathuru V. PCOSDB: PolyCystic Ovary Syndrome Database for manually curated disease associated genes. Bioinformation. 2016;12(1):4–8.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Dasgupta S, Reddy BM. Present status of understanding on the genetic etiology of polycystic ovary syndrome. J Postgrad Med. 2008;54(2):115–25.

    Article  CAS  PubMed  Google Scholar 

  9. Shi Y, Zhao H, Shi Y, Cao Y, Yang D, Li Z, et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet. 2012;44(9):1020–5.

    Article  CAS  PubMed  Google Scholar 

  10. Hayes MG, Urbanek M, Ehrmann DA, Armstrong LL, Lee JY, Sisk R, et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun. 2015;6:7502.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Layegh P, Mousavi Z, Farrokh Tehrani D, Parizadeh SM, Khajedaluee M. Insulin resistance and endocrine-metabolic abnormalities in polycystic ovarian syndrome: comparison between obese and non-obese PCOS patients. Int J Reprod Biomed (Yazd). 2016;14(4):263–70.

    Google Scholar 

  12. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83(5):1454–60.

    Article  CAS  PubMed  Google Scholar 

  13. Barbieri RL, Makris A, Ryan KJ. Insulin stimulates androgen accumulation in incubations of human ovarian stroma and theca. Obstet Gynecol. 1984;64(3 Suppl):73S–80S.

    Article  CAS  PubMed  Google Scholar 

  14. Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, et al. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 1991;72(1):83–9.

    Article  CAS  PubMed  Google Scholar 

  15. Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest. 1976;57(5):1320–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Mason HD, Willis DS, Beard RW, Winston RM, Margara R, Franks S. Estradiol production by granulosa cells of normal and polycystic ovaries: relationship to menstrual cycle history and concentrations of gonadotropins and sex steroids in follicular fluid. J Clin Endocrinol Metab. 1994;79(5):1355–60.

    CAS  PubMed  Google Scholar 

  17. Webber LJ, Stubbs S, Stark J, Trew GH, Margara R, Hardy K, et al. Formation and early development of follicles in the polycystic ovary. Lancet. 2003;362(9389):1017–21.

    Article  CAS  PubMed  Google Scholar 

  18. Korhonen S, Hippelainen M, Niskanen L, Vanhala M, Saarikoski S. Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study. Am J Obstet Gynecol. 2001;184(3):289–96.

    Article  CAS  PubMed  Google Scholar 

  19. Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(1):162–8.

    Article  CAS  PubMed  Google Scholar 

  20. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999;84(11):4006–11.

    Article  CAS  PubMed  Google Scholar 

  21. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85(7):2434–8.

    CAS  PubMed  Google Scholar 

  22. Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol. 1999;51(6):779–86.

    Article  CAS  Google Scholar 

  23. DeVane GW, Czekala NM, Judd HL, Yen SS. Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease. Am J Obstet Gynecol. 1975;121(4):496–500.

    Article  CAS  PubMed  Google Scholar 

  24. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90(4):1929–35.

    Article  CAS  PubMed  Google Scholar 

  25. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(1):48–53.

    Article  CAS  PubMed  Google Scholar 

  26. Cerda C, Perez-Ayuso RM, Riquelme A, Soza A, Villaseca P, Sir-Petermann T, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol. 2007;47(3):412–7.

    Article  CAS  PubMed  Google Scholar 

  27. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22(1):141–6.

    Article  CAS  PubMed  Google Scholar 

  28. Fogel RB, Malhotra A, Pillar G, Pittman SD, Dunaif A, White DP. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86(3):1175–80.

    CAS  PubMed  Google Scholar 

  29. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001;111(8):607–13.

    Article  CAS  PubMed  Google Scholar 

  30. Deeks AA, Gibson-Helm ME, Teede HJ. Anxiety and depression in polycystic ovary syndrome: a comprehensive investigation. Fertil Steril. 2010;93(7):2421–3.

    Article  PubMed  Google Scholar 

  31. Bhattacharya SM, Jha A. Prevalence and risk of depressive disorders in women with polycystic ovary syndrome (PCOS). Fertil Steril. 2010;94(1):357–9.

    Article  PubMed  Google Scholar 

  32. Zawadski J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Dunaif A, Givens J, Haseltine F, Merriam G, editors. Polycystic Ovary Syndrome (Current Issues in Endocrinology and Metabolism): Blackwell Scientific Inc.; 1992. p. 377–84.

  33. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7.

    Article  Google Scholar 

  34. •• Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–92. Recent and comprehensive synthesis of PCOS-related clinical practice guidelines and supporting evidence by the Endocrine Society.

    Article  CAS  PubMed  Google Scholar 

  35. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–7.

    Article  CAS  PubMed  Google Scholar 

  36. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981;140(7):815–30.

    Article  CAS  PubMed  Google Scholar 

  37. Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med. 2005;353(24):2578–88.

    Article  CAS  PubMed  Google Scholar 

  38. DeUgarte CM, Woods KS, Bartolucci AA, Azziz R. Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J Clin Endocrinol Metab. 2006;91(4):1345–50.

    Article  CAS  PubMed  Google Scholar 

  39. Ichikawa Y, Asai M, Masahashi T, Wu MC, Ohsawa M, Narita O, et al. Clinical assessment of body hair growth in Japanese women. The relationship between a grade of hirsutism and the menstrual status. Nihon Sanka Fujinka Gakkai Zasshi. 1988;40(11):1719–24.

    CAS  PubMed  Google Scholar 

  40. Kim JJ, Chae SJ, Choi YM, Hwang SS, Hwang KR, Kim SM, et al. Assessment of hirsutism among Korean women: results of a randomly selected sample of women seeking pre-employment physical check-up. Hum Reprod. 2011;26(1):214–20.

    Article  PubMed  Google Scholar 

  41. Sagsoz N, Kamaci M, Orbak Z. Body hair scores and total hair diameters in healthy women in the Kirikkale Region of Turkey. Yonsei Med J. 2004;45(3):483–91.

    Article  PubMed  Google Scholar 

  42. Cibula D, Hill M, Starka L. The best correlation of the new index of hyperandrogenism with the grade of increased body hair. Eur J Endocrinol. 2000;143(3):405–8.

    Article  CAS  PubMed  Google Scholar 

  43. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666–72.

    Article  CAS  PubMed  Google Scholar 

  44. • Bui HN, Sluss PM, Hayes FJ, Blincko S, Knol DL, Blankenstein MA, et al. Testosterone, free testosterone, and free androgen index in women: Reference intervals, biological variation, and diagnostic value in polycystic ovary syndrome. Clin Chim Acta. 2015;450:227–32. Analysis of second generation immunoassays and LC/MS for androgen measurement in healthy and PCOS women. Demonstrates the importance of understanding the assay used by the clinical laboratory.

    Article  CAS  PubMed  Google Scholar 

  45. Bui HN, Sluss PM, Blincko S, Knol DL, Blankenstein MA, Heijboer AC. Dynamics of serum testosterone during the menstrual cycle evaluated by daily measurements with an ID-LC-MS/MS method and a 2nd generation automated immunoassay. Steroids. 2013;78(1):96–101.

    Article  CAS  PubMed  Google Scholar 

  46. Garde AH, Hansen AM, Skovgaard LT, Christensen JM. Seasonal and biological variation of blood concentrations of total cholesterol, dehydroepiandrosterone sulfate, hemoglobin A(1c), IgA, prolactin, and free testosterone in healthy women. Clin Chem. 2000;46(4):551–9.

    CAS  PubMed  Google Scholar 

  47. • Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007;92(2):405–13. Review of serious problems in testosterone measurements used by clinical laboratories, and a call to improve accuracy, precision and clinical relevance of T testing.

    Article  CAS  PubMed  Google Scholar 

  48. Thienpont LM, Van Uytfanghe K, Blincko S, Ramsay CS, Xie H, Doss RC, et al. State-of-the-art of serum testosterone measurement by isotope dilution-liquid chromatography-tandem mass spectrometry. Clin Chem. 2008;54(8):1290–7.

    Article  CAS  PubMed  Google Scholar 

  49. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88(12):5957–62.

    Article  CAS  PubMed  Google Scholar 

  50. Eilertsen TB, Vanky E, Carlsen SM. Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced? Hum Reprod. 2012;27(8):2494–502.

    Article  CAS  PubMed  Google Scholar 

  51. Hart R, Doherty DA, Norman RJ, Franks S, Dickinson JE, Hickey M, et al. Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril. 2010;94(3):1118–21.

    Article  CAS  PubMed  Google Scholar 

  52. Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab. 2013;98(8):3332–40.

    Article  CAS  PubMed  Google Scholar 

  53. Bhide P, Homburg R. Anti-Mullerian hormone and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2016.

  54. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219–31.

    Article  CAS  PubMed  Google Scholar 

  55. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Endocr Pract. 2005;11(2):126–34.

    Google Scholar 

  56. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary syndrome—a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007;92(12):4546–56.

    Article  CAS  PubMed  Google Scholar 

  57. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab. 2005;90(6):3236–42.

    Article  CAS  PubMed  Google Scholar 

  58. Pasquali R, Gambineri A, Cavazza C, Ibarra Gasparini D, Ciampaglia W, Cognigni GE, et al. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol. 2011;164(1):53–60.

    Article  CAS  PubMed  Google Scholar 

  59. Bates GW, Whitworth NS. Effect of body weight reduction on plasma androgens in obese, infertile women. Fertil Steril. 1982;38(4):406–9.

    Article  CAS  PubMed  Google Scholar 

  60. Guzick DS, Wing R, Smith D, Berga SL, Winters SJ. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril. 1994;61(4):598–604.

    Article  CAS  PubMed  Google Scholar 

  61. Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod. 2003;18(9):1928–32.

    Article  PubMed  Google Scholar 

  62. Legro RS, Dodson WC, Kunselman AR, Stetter CM, Kris-Etherton PM, Williams NI, et al. Benefit of delayed fertility therapy with preconception weight loss over immediate therapy in obese women with PCOS. J Clin Endocrinol Metab. 2016;101(7):2658–66.

    Article  CAS  PubMed  Google Scholar 

  63. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril. 2008;89(3):505–22.

    Article  Google Scholar 

  64. •• Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 371(2):119–29. Practice-changing, well-designed randomized trial demonstrating superiority of Letrozole over Clomiphene in ovulation induction for infertility treatment.

  65. Franik S, Kremer JA, Nelen WL, Farquhar C. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 24(2):CD010287.

  66. Seyedoshohadaei F, Tangestani L, Zandvakili F, Rashadmanesh N. Comparison of the effect of clomiphene-estradiol valerate vs letrozole on endometrial thickness, abortion and pregnancy rate in infertile women with polycystic ovarian syndrome. J Clin Diagn Res. 2016;10(8):QC10–3.

    PubMed  PubMed Central  Google Scholar 

  67. Wu CH, Winkel CA. The effect of therapy initiation day on clomiphene citrate therapy. Fertil Steril. 1989;52(4):564–8.

    Article  CAS  PubMed  Google Scholar 

  68. Abu Hashim H, Bazeed M, Abd EI. Minimal stimulation or clomiphene citrate as first-line therapy in women with polycystic ovary syndrome: a randomized controlled trial. Gynecol Endocrinol. 2012;28(2):87–90.

    Article  CAS  PubMed  Google Scholar 

  69. Dickey RP, Holtkamp DE. Development, pharmacology and clinical experience with clomiphene citrate. Hum Reprod Update. 1996;2(6):483–506.

    Article  CAS  PubMed  Google Scholar 

  70. Hughes E, Brown J, Collins JJ, Vanderkerchove P. Clomiphene citrate for unexplained subfertility in women. Cochrane Database Syst Rev. 2010;20(1):CD000057.

    Google Scholar 

  71. Bhattacharya S, Harrild K, Mollison J, Wordsworth S, Tay C, Harrold A, et al. Clomifene citrate or unstimulated intrauterine insemination compared with expectant management for unexplained infertility: pragmatic randomised controlled trial. BMJ. 2008;337:a716.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Al-Fadhli R, Sylvestre C, Buckett W, Tan SL, Tulandi T. A randomized trial of superovulation with two different doses of letrozole. Fertil Steril. 2006;85(1):161–4.

    Article  CAS  PubMed  Google Scholar 

  73. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril. 2001;75(2):310–5.

    Article  CAS  PubMed  Google Scholar 

  74. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007;356(6):551–66.

    Article  CAS  PubMed  Google Scholar 

  75. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ. 2006;332(7556):1485.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012;16(5):CD003053.

    Google Scholar 

  77. Wang CF, Gemzell C. The use of human gonadotropins for the induction of ovulation in women with polycystic ovarian disease. Fertil Steril. 1980;33(5):479–86.

    Article  CAS  PubMed  Google Scholar 

  78. White DM, Polson DW, Kiddy D, Sagle P, Watson H, Gilling-Smith C, et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab. 1996;81(11):3821–4.

    CAS  PubMed  Google Scholar 

  79. Eijkemans MJ, Imani B, Mulders AG, Habbema JD, Fauser BC. High singleton live birth rate following classical ovulation induction in normogonadotrophic anovulatory infertility (WHO 2). Hum Reprod. 2003;18(11):2357–62.

    Article  PubMed  Google Scholar 

  80. Abu HH. Predictors of success of laparoscopic ovarian drilling in women with polycystic ovary syndrome: an evidence-based approach. Arch Gynecol Obstet. 2015;291(1):11–8.

    Article  Google Scholar 

  81. Farquhar C, Brown J, Marjoribanks J. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev. 2012;13(6):CD001122.

    Google Scholar 

  82. Moazami Goudarzi Z, Fallahzadeh H, Aflatoonian A, Mirzaei M. Laparoscopic ovarian electrocautery versus gonadotropin therapy in infertile women with clomiphene citrate-resistant polycystic ovary syndrome: a systematic review and meta-analysis. Iran J Reprod Med. 2014;12(8):531–8.

    PubMed  PubMed Central  Google Scholar 

  83. Farquhar CM, Williamson K, Gudex G, Johnson NP, Garland J, Sadler L. A randomized controlled trial of laparoscopic ovarian diathermy versus gonadotropin therapy for women with clomiphene citrate-resistant polycystic ovary syndrome. Fertil Steril. 2002;78(2):404–11.

    Article  PubMed  Google Scholar 

  84. van Wely M, Bayram N, Bossuyt PM, van der Veen F. Laparoscopic electrocautery of the ovaries versus recombinant FSH in clomiphene citrate-resistant polycystic ovary syndrome. Impact on women's health-related quality of life. Hum Reprod. 2004;19(10):2244–50.

    Article  PubMed  Google Scholar 

  85. Bayram N, van Wely M, van der Veen F, Bossuyt PM, Nieuwkerk P. Treatment preferences and trade-offs for ovulation induction in clomiphene citrate-resistant patients with polycystic ovary syndrome. Fertil Steril. 2005;84(2):420–5.

    Article  PubMed  Google Scholar 

  86. Heijnen EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12(1):13–21.

    Article  CAS  PubMed  Google Scholar 

  87. Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Freitas V. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2009;15(2):CD006105.

    Google Scholar 

  88. •• Palomba S, Falbo A, La Sala GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG. 2013;120(3):267–76. Important analysis of metformin utility in IVF/ICSI: reduces complications (OHSS), but does not alter pregnancy rates and live birth. Subset analysis of only one RCT suggests improvement in miscarriage rate at higher doses and administration until 12 weeks.

    Article  CAS  PubMed  Google Scholar 

  89. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):748–58.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000;85(1):139–46.

    CAS  PubMed  Google Scholar 

  91. Unluhizarci K, Kelestimur F, Bayram F, Sahin Y, Tutus A. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin Endocrinol. 1999;51(2):231–6.

    Article  CAS  Google Scholar 

  92. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007;24(1):CD005552.

    Google Scholar 

  93. Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, Williams NI, et al. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol. 2007;196(4):402. e1-10; discussion 402.e10-1

    Article  PubMed  Google Scholar 

  94. Martin KA, Chang RJ, Ehrmann DA, Ibanez L, Lobo RA, Rosenfield RL, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(4):1105–20.

    Article  CAS  PubMed  Google Scholar 

  95. Fitzgerald C, Elstein M, Spona J. Effect of age on the response of the hypothalamo-pituitary-ovarian axis to a combined oral contraceptive. Fertil Steril. 1999;71(6):1079–84.

    Article  CAS  PubMed  Google Scholar 

  96. Domecq JP, Prutsky G, Mullan RJ, Sundaresh V, Wang AT, Erwin PJ, et al. Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2013;98(12):4646–54.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Infertility and Reproductive Surgery, Department of Ob/Gyn, Brigham and Women’s Hospital and Harvard Medical School, 75 Francis Street, ASB 1-3, Boston, MA, 02115, USA

    Phillip Romanski

  2. Division of Reproductive Sciences, Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, WI, USA

    Aleksandar K. Stanic

Authors
  1. Phillip Romanski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aleksandar K. Stanic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Phillip Romanski.

Ethics declarations

Conflict of Interest

Phillip Romanski and Aleksandar K. Stanic declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Reproductive Endocrinology and Infertility (REI)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Romanski, P., Stanic, A.K. Practical Approach to the PCOS Patient. Curr Obstet Gynecol Rep 6, 11–20 (2017). https://doi.org/10.1007/s13669-017-0190-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13669-017-0190-6

Keywords

Search

Navigation